However, the counterfeit drugs do not only harm those who take them. Also from a business and economic perspective, the problem is quiet significant: reputable pharmaceutical companies, manufacturers, distributors and importers are losing billions. In addition, ineffective or health-threatening plagiarisms of globally known drugs destroy the reputation of the originals. Last but not least, the state not only misses taxes when counterfeit medicines are bought online, but in the worst-case costs arise in the health care system when patients need medical care after taking them. If only for this reason, the responsible institutions should have an even greater interest in the anti-counterfeiting of medical products. Manufacturers of branded products are therefore increasingly relying on technical security means for copy protection, authentication and distribution control of their goods. But security marks such as the GS mark or the CE mark as market conformity mark are unfortunately no longer an indication of original products. These marks are just as often counterfeited as the original products themselves. (Consumers find access to databases and purchasing helps for tested products at www.produktpiraterie.org). As a result, digitization is an important partner in the fight against counterfeit drugs. Thanks to digitization, the identification features of prescription-only drugs, which have been in force since February 2019, are now possible using a data matrix barcode and database comparison. In Germany, the system for authentication of drugs is called SecurPharm. Users of the system are hospitals, pharmacies, wholesalers and pharmaceutical companies. Some features, such as logistics seals or colour pigments can only be read by the authorities, such as customs, with appropriate readers. Others, such as holograms or first-opening seals, can also be recognized by the end users.